COVID-19
Overview
During the COVID-19 pandemic, our group shifted their focus to developing effective treatments for this devastating disease. Realizing that many patients who became critically ill with COVID-19 generated insufficient endogenous immune responses, we worked in collaboration with Eli Lilly and Company to perform first in human testing of monoclonal antibodies against the SARS-CoV-2 spike protein. Working on these antibodies from Phase 1 through Phase 3 testing, we established that monoclonal antibody therapy for SARS-CoV-2 is safe and if given early in disease can decrease the risk of hospitalization and death by 80%. Today, Dr. Dougan remains a member of the MGH COVID-19 Scientific Review and Clinical Trials Steering Committees, and is co-chair of the MGH COVID-19 Clinical Trials Implementation Committee.
Completed trials
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Particpants with Mild to Moderate COVID-19 (BLAZE-1)
Sponsor: Eli Lilly and Company
A randomized, double-blind, placebo controlled clinical trial measuring how well bamlanivimab, etesevimab, and bebtelovimab work against the virus that causes COVID-19 in high-risk and pediatric patients.
A Study of Immune System Proteins in Participants with Mild to Moderate COVID-19 Illness (BLAZE-4)
Sponsor: Eli Lilly and Company
A randomized, double-blind, placebo controlled clinical trial measuring how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19 in high and low-risk patients.
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
Sponsor: Eli Lilly and Company
A randomized, double-blind, placebo controlled clinical trial testing the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19.
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals
Sponsor: Brigham & Women’s Hospital, GSK
Open-label clinical trial evaluating the safety and tolerability of sotrovimab, administered in two sequential doses, as COVID-19 prophylaxis in immunocompromised patients with impaired humoral immunity against SARS-CoV-2.
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
Sponsor: Pfizer
A randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814 in patients hospitalized with COVID-19.